Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6422943 | 1.00 | AKR1C3 (0.34) | AKR1C3AKR1C2PTGS2PTGS1MAOB | |
| SCHEMBL6462992 | 0.97 | AKR1C3 (0.33) | AKR1C3AKR1C2PTGS2PTGS1MAOB | |
| SCHEMBL6424020 | 0.95 | AKR1C3 (0.35) | AKR1C3AKR1C2PTGS2PTGS1MAOB | |
| SCHEMBL6462017 | 0.95 | AKR1C3 (0.35) | AKR1C3AKR1C2PTGS2PTGS1MAOB | |
| SCHEMBL6423934 | 0.94 | TSHR (0.35) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| SCHEMBL6424801 | 0.94 | TSHR (0.35) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| SCHEMBL6426388 | 0.92 | AKR1C3 (0.33) | AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL6424378 | 0.92 | AKR1C3 (0.33) | AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL6427345 | 0.91 | TSHR (0.35) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| SCHEMBL6423583 | 0.91 | AKR1C3 (0.36) | AKR1C3AKR1C2PTGS2PTGS1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | AKR1C3 577/4885AKR1C2 563/4885PTGS2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.